JP2008504235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008504235A5 JP2008504235A5 JP2007512734A JP2007512734A JP2008504235A5 JP 2008504235 A5 JP2008504235 A5 JP 2008504235A5 JP 2007512734 A JP2007512734 A JP 2007512734A JP 2007512734 A JP2007512734 A JP 2007512734A JP 2008504235 A5 JP2008504235 A5 JP 2008504235A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- branched
- cancer
- linear
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000000732 arylene group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- -1 4-carboxybenzyl Chemical group 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000005724 cycloalkenylene group Chemical group 0.000 claims 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 101710183280 Topoisomerase Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000002141 anti-parasite Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000013256 coordination polymer Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 CC(C(NC(Cc1ccccc1)C(NC(CC(O)=O)C(NCC1OC1NC1CCCN*C(N)=N)=O)=O)=O)NC1=O Chemical compound CC(C(NC(Cc1ccccc1)C(NC(CC(O)=O)C(NCC1OC1NC1CCCN*C(N)=N)=O)=O)=O)NC1=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2004A000240 | 2004-05-13 | ||
| IT000240A ITRM20040240A1 (it) | 2004-05-13 | 2004-05-13 | Camptotecine coniugate in posizione 7 con antagonisti delle integrine. |
| PCT/IT2005/000260 WO2005111063A1 (en) | 2004-05-13 | 2005-05-04 | Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008504235A JP2008504235A (ja) | 2008-02-14 |
| JP2008504235A5 true JP2008504235A5 (enExample) | 2008-06-26 |
| JP4805917B2 JP4805917B2 (ja) | 2011-11-02 |
Family
ID=34968014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007512734A Expired - Fee Related JP4805917B2 (ja) | 2004-05-13 | 2005-05-04 | 細胞分裂阻害剤として７位にて環状ペプチドと接合したカンプトテシン |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7705012B2 (enExample) |
| EP (1) | EP1753776B1 (enExample) |
| JP (1) | JP4805917B2 (enExample) |
| KR (1) | KR101145815B1 (enExample) |
| CN (1) | CN1953989B (enExample) |
| AR (1) | AR048949A1 (enExample) |
| AT (1) | ATE420891T1 (enExample) |
| AU (1) | AU2005243417B2 (enExample) |
| BR (1) | BRPI0510983A (enExample) |
| CA (1) | CA2563708A1 (enExample) |
| CY (1) | CY1108985T1 (enExample) |
| DE (1) | DE602005012390D1 (enExample) |
| DK (1) | DK1753776T3 (enExample) |
| ES (1) | ES2321114T3 (enExample) |
| HR (1) | HRP20090146T3 (enExample) |
| IT (1) | ITRM20040240A1 (enExample) |
| MX (1) | MXPA06012884A (enExample) |
| PL (1) | PL1753776T3 (enExample) |
| PT (1) | PT1753776E (enExample) |
| RS (1) | RS51169B (enExample) |
| SI (1) | SI1753776T1 (enExample) |
| TW (1) | TWI352703B (enExample) |
| WO (1) | WO2005111063A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20040239A1 (it) * | 2004-05-13 | 2004-08-13 | Sigma Tau Ind Farmaceuti | Derivati ciclopeptidici ad attivita' antintegrine. |
| US8853233B2 (en) * | 2007-02-13 | 2014-10-07 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives |
| TW201004647A (en) * | 2008-05-20 | 2010-02-01 | Sigma Tau Ind Farmaceuti | Novel dual targeting antitumoural conjugates |
| WO2011002852A2 (en) * | 2009-06-30 | 2011-01-06 | The Regents Of The University Of Michigan | Pro-drug complexes and related methods of use |
| US9073974B2 (en) | 2009-12-21 | 2015-07-07 | The Regents Of The University Of California | RGD-containing cyclic peptides |
| WO2011100688A1 (en) | 2010-02-12 | 2011-08-18 | Dana-Farber Cancer Institute, Inc. | Improved antagonists of muc1 |
| WO2013026015A1 (en) | 2011-08-18 | 2013-02-21 | Dana-Farber Cancer Institute, Inc. | Muc1 ligand traps for use in treating cancers |
| CN102516258B (zh) * | 2011-11-11 | 2014-06-25 | 正大天晴药业集团股份有限公司 | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 |
| US9044421B2 (en) | 2012-03-28 | 2015-06-02 | Genus Oncology, Llc | Treating MUC1-expressing cancers with combination therapies |
| EP3310787B9 (en) * | 2015-06-18 | 2020-07-01 | Ramot at Tel-Aviv University Ltd. | Taggable heteroaromatic drugs and conjugates thereof |
| US10494403B2 (en) * | 2018-03-06 | 2019-12-03 | Ciphore Biomed Technology Limited Company | Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same |
| CN115590975A (zh) * | 2022-11-15 | 2023-01-13 | 无锡福祈制药有限公司（Cn） | 丝裂霉素-rgd肽偶联物及其制备方法 |
| CN120078902A (zh) * | 2023-12-01 | 2025-06-03 | 深圳碳云智肽药物科技有限公司 | 一种多肽偶联喜树碱衍生物及其抗肿瘤应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE136898T1 (de) * | 1991-10-29 | 1996-05-15 | Glaxo Wellcome Inc | Wasserlösliche camptothecinderivate |
| US5646159A (en) * | 1994-07-20 | 1997-07-08 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
| CA2192725C (en) | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| ES2262223T3 (es) * | 1997-02-14 | 2006-11-16 | Bionumerik Pharmaceuticals, Inc. | Derivados de camptotecina altamente lipofilos. |
| DE19815812A1 (de) | 1998-04-08 | 1999-10-14 | Bayer Ag | Modifizierte Cytostatika |
| EP1044977B1 (en) | 1999-03-09 | 2002-05-02 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Camptothecin derivatives having antitumor activity |
| JP2003508497A (ja) * | 1999-09-08 | 2003-03-04 | バイエル アクチェンゲゼルシャフト | インテグリンに媒介される薬物ターゲッティング |
| IL155139A0 (en) * | 2000-10-06 | 2003-10-31 | Novartis Ag | Targeting molecules for adenoviral vectors |
| WO2002096367A2 (en) * | 2001-05-30 | 2002-12-05 | Targesome, Inc. | Targeted multivalent macromolecules |
-
2004
- 2004-05-13 IT IT000240A patent/ITRM20040240A1/it unknown
-
2005
- 2005-04-25 TW TW094113142A patent/TWI352703B/zh not_active IP Right Cessation
- 2005-05-04 ES ES05742726T patent/ES2321114T3/es not_active Expired - Lifetime
- 2005-05-04 DK DK05742726T patent/DK1753776T3/da active
- 2005-05-04 CN CN2005800152338A patent/CN1953989B/zh not_active Expired - Fee Related
- 2005-05-04 PL PL05742726T patent/PL1753776T3/pl unknown
- 2005-05-04 CA CA002563708A patent/CA2563708A1/en not_active Abandoned
- 2005-05-04 MX MXPA06012884A patent/MXPA06012884A/es active IP Right Grant
- 2005-05-04 EP EP05742726A patent/EP1753776B1/en not_active Expired - Lifetime
- 2005-05-04 DE DE602005012390T patent/DE602005012390D1/de not_active Expired - Lifetime
- 2005-05-04 JP JP2007512734A patent/JP4805917B2/ja not_active Expired - Fee Related
- 2005-05-04 BR BRPI0510983-3A patent/BRPI0510983A/pt not_active IP Right Cessation
- 2005-05-04 AU AU2005243417A patent/AU2005243417B2/en not_active Ceased
- 2005-05-04 KR KR1020067025552A patent/KR101145815B1/ko not_active Expired - Fee Related
- 2005-05-04 HR HR20090146T patent/HRP20090146T3/xx unknown
- 2005-05-04 PT PT05742726T patent/PT1753776E/pt unknown
- 2005-05-04 US US11/596,015 patent/US7705012B2/en not_active Expired - Fee Related
- 2005-05-04 SI SI200530601T patent/SI1753776T1/sl unknown
- 2005-05-04 RS RSP-2009/0152A patent/RS51169B/sr unknown
- 2005-05-04 AT AT05742726T patent/ATE420891T1/de active
- 2005-05-04 WO PCT/IT2005/000260 patent/WO2005111063A1/en not_active Ceased
- 2005-05-11 AR ARP050101902A patent/AR048949A1/es unknown
-
2009
- 2009-04-10 CY CY20091100424T patent/CY1108985T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008504235A5 (enExample) | ||
| EA200000274A2 (ru) | Способы получения и промежуточные соединения для получения противораковых соединений | |
| CY1109449T1 (el) | Ενωσεις ουριας δραστικες ως ανταγωνιστες βανιλλοειδων υποδοχεων για την αντιμετωπιση του πονου | |
| JP2008535902A5 (enExample) | ||
| EA200801998A1 (ru) | ПИРИДИН[3,4-b]ПИРАЗИНОНЫ | |
| CY1113323T1 (el) | Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου | |
| EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
| CY1113538T1 (el) | Παραγωγα της 5-αμινο-2,4,7-τριοξο-3,4,7,8-τετραϋδρο-2η-πυριδο[2,3-d] πυριμιδινης και παρομοιες ενωσεις για την αγωγη του καρκινου | |
| MX2010003868A (es) | Cis-imidazolinas quirales. | |
| CY1117470T1 (el) | Στερεα δοσολογικα σκευασματα με βελτιωμενη ενδοστοματικη προσροφηση | |
| CY1110332T1 (el) | Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους | |
| BR0009338A (pt) | Composto, processo para a preparação do mesmo,composição farmacêutica, processo para apreparação da mesma, uso de um composto, e,método de tratamento de uma doençainflamatória em um paciente sofrendo ou em riscode dita doença | |
| EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
| NO20072515L (no) | 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav | |
| SA521421855B1 (ar) | مترافقات عقار-جسم مضاد | |
| JP2020508985A5 (enExample) | ||
| JPWO2020260252A5 (enExample) | ||
| JP2009526076A5 (enExample) | ||
| US20200297693A1 (en) | Glucose conjugates of triptolide, analogs and uses thereof | |
| CY1114140T1 (el) | Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο | |
| IL153680A0 (en) | Aplidine derivatives and methods for the preparation thereof | |
| SE0402925D0 (sv) | Novel Compounds | |
| EE200000472A (et) | Kasvajavastased toimeained | |
| EP4294820A1 (en) | Cyclic cell-penetrating peptides with three or more hydrophobic residues | |
| CA2563708A1 (en) | Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents |